Terms: = Ovarian epithelial cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
296 results:
1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer.
Colombo PE; Taoum C; Fabbro M; Quesada S; Rouanet P; Ray-Coquard I
Crit Rev Oncol Hematol; 2024 Oct; 202():104469. PubMed ID: 39111459
[TBL] [Abstract] [Full Text] [Related]
2. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
[TBL] [Abstract] [Full Text] [Related]
3. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
Ma MC; Lavi ES; Altwerger G; Lin ZP; Ratner ES
PLoS One; 2024; 19(7):e0305273. PubMed ID: 38976671
[TBL] [Abstract] [Full Text] [Related]
4. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8
Park J; Kim JC; Lee YJ; Kim S; Kim SW; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964784
[TBL] [Abstract] [Full Text] [Related]
5. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; ; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Gilks CB; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Soong TR; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
Clin Cancer Res; 2024 Aug; 30(16):3481-3498. PubMed ID: 38837893
[TBL] [Abstract] [Full Text] [Related]
6. epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.
Xu Y; Xiong F; Li H; Zheng H; Jiang J; Li Q; Li G; Zhao W; Li R; Li J; Xie R; An R; Zhang H; Gao Q
Int J Gynecol Cancer; 2024 Sep; 34(9):1461-1465. PubMed ID: 38658024
[TBL] [Abstract] [Full Text] [Related]
8. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
9. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract] [Full Text] [Related]
10. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
[TBL] [Abstract] [Full Text] [Related]
11. Successful Management of ovarian cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.
Endo Y; Kamo N; Kato A; Sato T; Okabe C; Furukawa S; Watanabe T; Soeda S
In Vivo; 2024; 38(2):958-962. PubMed ID: 38418162
[TBL] [Abstract] [Full Text] [Related]
12. brca1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract] [Full Text] [Related]
13. Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Nicum S; McGregor N; Austin R; Collins L; Dutton S; McNeish I; Glasspool R; Hall M; Roux R; Michael A; Clamp A; Jayson G; Kristeleit R; Banerjee S; Mansouri A
Br J Cancer; 2024 Apr; 130(6):941-950. PubMed ID: 38245661
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract] [Full Text] [Related]
15. Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in ovarian cancer Patients: A Comparison with Myriad MyChoice Assay.
Scaglione GL; Pignata S; Pettinato A; Paolillo C; Califano D; Scandurra G; Lombardo V; Di Gaudio F; Pecorino B; Mereu L; Scollo P; Capoluongo ED
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069422
[TBL] [Abstract] [Full Text] [Related]
16. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB
PLoS One; 2023; 18(11):e0294647. PubMed ID: 37976295
[TBL] [Abstract] [Full Text] [Related]
17. Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed ovarian cancer: A Phase II Multi-Cohort Study.
Drew Y; Kim JW; Penson RT; O'Malley DM; Parkinson C; Roxburgh P; Plummer R; Im SA; Imbimbo M; Ferguson M; Rosengarten O; Steeghs N; Kim MH; Gal-Yam E; Tsoref D; Kim JH; You B; De Jonge M; Lalisang R; Gort E; Bastian S; Meyer K; Feeney L; Baker N; Ah-See ML; Domchek SM; Banerjee S;
Clin Cancer Res; 2024 Jan; 30(1):50-62. PubMed ID: 37939124
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract] [Full Text] [Related]
19. Causality and functional relevance of brca1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
Kramer C; Lanjouw L; Ruano D; Ter Elst A; Santandrea G; Solleveld-Westerink N; Werner N; van der Hout AH; de Kroon CD; van Wezel T; Berger L; Jalving M; Wesseling J; Smit V; de Bock GH; van Asperen CJ; Mourits M; Vreeswijk M; Bart J; Bosse T
J Pathol; 2024 Feb; 262(2):137-146. PubMed ID: 37850614
[TBL] [Abstract] [Full Text] [Related]
20. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous ovarian cancer and Clear Cell ovarian Carcinoma.
Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
[TBL] [Abstract] [Full Text] [Related]
[Next]
